<div><div></div><div>Cue Biopharma announced a series of agreements highlighted by an exclusive license for Ascendant-221 (anti-IgE) from Ascendant Health Sciences, including a $15.0 million upfront payment, up to $676.5 million in milestones, and tiered royalties. To align interests, Cue will issue Ascendant pre-funded warrants for up to 551,724 shares with a potential top-up to at least 7.5% ownership upon milestone achievement, alongside lock-up, standstill, and voting commitments. Separately, Cue agreed to a private placement expected to raise approximately $30 million through pre-funded warrants and five-year warrants priced at $11.00 per unit, and granted registration rights to the investors. The transactions support pipeline expansion and provide capital for development and corporate needs.Agreement 1: Cue Biopharma Licenses Anti-IgE Asset From Ascendant; $15M Upfront, Up to $676.5M in Milestones<ul><li>Agreement type: Exclusive worldwide (ex-Greater China) license for anti-IgE antibody and related products</li><li>Counterparty: Ascendant Health Sciences</li><li>Signed / Effective: Apr 30 2026 / Apr 30 2026</li><li>Duration / Termination: Per product Royalty Term; early termination rights</li><li>Reason: Expand pipeline with late-stage anti-IgE program and global rights</li></ul>Agreement 2: Cue Biopharma to Issue Pre-Funded Warrants to Ascendant; Potential Top-Up to 7.5% Ownership<ul><li>Agreement type: Securities Purchase Agreement for pre-funded warrants and potential equity top-up</li><li>Counterparty: Ascendant Health Sciences</li><li>Signed / Effective: Apr 30 2026 / Apr 30 2026</li><li>Duration / Termination: Pre-Funded Warrants exercisable up to 10 years after issuance</li><li>Reason: Align licensor via equity and support transaction structure</li></ul>Agreement 3: Cue Biopharma and Ascendant Enter Investor Agreement With Lock-Up and 18-Month Standstill<ul><li>Agreement type: Investor Agreement with lock-up, standstill, and voting provisions</li><li>Counterparty: Ascendant Health Sciences</li><li>Signed / Effective: Apr 30 2026 / Apr 30 2026</li><li>Duration / Termination: Lock-up 360 days; standstill 18 months</li><li>Reason: Support governance stability and orderly market post-transaction</li></ul>Agreement 4: Cue Biopharma Raises ~$30M via Private Placement of Pre-Funded Warrants and 5-Year Warrants<ul><li>Agreement type: Private placement of pre-funded warrants and five-year warrants</li><li>Counterparty: Accredited investors</li><li>Signed / Effective: Apr 30 2026 / Apr 30 2026</li><li>Duration / Termination: Warrants exercisable 5 years; Pre-Funded Warrants no stated expiry</li><li>Reason: Raise capital to fund development and corporate needs</li></ul>Agreement 5: Cue Biopharma Grants Registration Rights for Resale of Private Placement Warrant Shares<ul><li>Agreement type: Registration Rights Agreement for resale of warrant shares</li><li>Counterparty: Accredited investors</li><li>Signed / Effective: Apr 30 2026 / Apr 30 2026</li><li>Duration / Termination: Until resale completed or securities cease to be registrable</li><li>Reason: Provide liquidity and protections to new investors</li></ul>Original SEC Filing: Cue Biopharma, Inc. [ CUE ] - 8-K - Apr. 30, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

Cue Biopharma has secured an exclusive license for the anti-IgE asset Ascendant-221 from Ascendant Health Sciences, involving a $15 million upfront payment and potential milestones totaling up to $676.5 million. The agreement includes pre-funded warrants for Ascendant, allowing for a potential 7.5% ownership stake. Additionally, Cue plans to raise approximately $30 million through a private placement of warrants. These transactions aim to expand Cue's pipeline and support its development and corporate needs.